BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.19 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this drugmaker would post a loss of $0.19 per share when it actually produced a loss of$0.06, delivering a surprise of 68.42%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.BioCryst, which belongs to the ...